Cognitive impairment risk increased in hypertensive patients with progressive cerebral small vessel disease

DALLAS, January 4, 2019 – Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of cognitive impairment despite taking medication to lower their blood pressure, according to new research in the American Heart Association’s journal Hypertension.

High blood pressure has been linked to an increased risk for dementia, but what’s unclear is what kinds of subtle negative changes take place in the brain that may affect cognitive function. Finding new ways to detect minor types of cognitive impairment may help determine who is at risk for early-stage dementia.

In this study, researchers looked at 345 men and women with a median age of 65 who had high blood pressure. Patients underwent brain imaging scans, were tested in cognitive function areas including execution, memory and attention, and were followed for about four years. Patients’ average blood pressure during follow-up was 144.5/76.5 mm Hg. The American Heart Association/American College of Cardiology 2017 hypertension guidelines revised the definition of hypertension and classified it as a blood pressure reading of 130/80 mm Hg instead of 140/90.

To understand what was going on in the brain, researchers looked at the brain’s white matter. White matter is important because it connects different regions of the brain, serving as a kind of infrastructure. Specifically, researchers looked at periventricular white matter, located in the central part of the brain. Periventricular white matter acts as a bridge between distant brain regions and serves an important role in cognitive function. Lesions or abnormalities found in periventricular white matter could signal cognitive impairment.

During the study, 9 percent of the group developed mild cognitive impairment which may increase the risk for dementia. There was also a connection for periventricular white matter changes and the risk of mild cognitive impairment. Researchers found that patients with a progression of periventricular white matter abnormalities showed a six-fold increased risk of mild cognitive decline.

The study observed that the progression of periventricular white matter abnormalities aligned with cognitive decline in global and executive function; small vessel bleeding in the brain was found to be related to a decline in attention.

Although the development of brain lesions may be considered “silent” conditions in which patients do not feel or are unaware of symptoms, if left untreated, the risks of more severe forms of cognitive decline may increase. Researchers say more study is needed to better understand how periventricular white matter changes triggers cognitive decline.

“The brain is an organ exposed to a high volume of blood flow and it is very vulnerable to sustained high blood pressure levels, and this might be happening silently or with mild symptoms, but that doesn’t mean there aren’t consequences,” said lead author Joan Jiménez Balado, Ph.D. student, Psychologist, M.Sc. in NeuroscienceC at the Institut de Recerca Hospital Vall d’Hebron in Barcelona, Spain. “High blood pressure and its consequences are really ‘covert’ diseases that tend to progress if it is not well managed.”

###

Co-authors: Iolanda Riba-Llena, M.D., Ph.D.; Oscar Abril, B.Sc.; Edurne Garde, M.Sc.; Anna Penalba, B.Sc.; Elena Ostos, B.Sc.; Olga Maisterra, M.D., Ph.D.; Joan Montaner, M.D., Ph.D.; Maria Noviembre, M.Sc.; Xavier Mundet, M.D., Ph.D.; Oriol Ventura, B.Sc.; Jesus Pizarro, B.Sc.; Pilar Delgado, M.D., Ph.D.

This research was funded by the Instituto de Salud Carlos III and AGAUR, with the support of the Secretary of Universities and Research of the Department of Economy and Knowledge (Generalitat de Catalunya) and co-financed by the European Regional Development Fund.

Additional Resources:

• Available multimedia located on the right column of the release: https://newsroom.heart.org/news/cognitive-impairment-risk-increased-in-hypertensive-patients-with-progressive-cerebral-small-vessel-disease?preview=629a228350c912910b0dd9056c06b9c9
• After January 4, view the manuscript online.
• Follow AHA/ASA news on Twitter @HeartNews

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.heart.org/corporatefunding.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.